<![CDATA[FDA Accepts NDA for Apnimed’s AD109 for the Treatment of Obstructive Sleep Apnea]]>
Post Content: Source: Neurology Read More
<![CDATA[FDA Accepts NDA for Axsome Therapeutics’ AXS-12 for the Treatment of Cataplexy in Narcolepsy]]>
Post Content: Source: Neurology Read More
<![CDATA[Using Sensory-Based Interventions for Older Adults With Dementia: Elizabeth Rhodus, PhD, MS, OTR/L]]>
Post Content: Source: Neurology Read More
<![CDATA[NeuroVoices: Jeff Dage, PhD, on Clinical Implementation of Blood-Based Biomarkers in Alzheimer Disease ]]>
<![CDATA[Optimizing Amyloid Biomarker Use to Guide Antiamyloid Immunotherapy Eligibility in Alzheimer Disease: Suzanne Schindler, MD, PhD]]>
<![CDATA[Long-Term Brain Health in Former Soccer Players: Caleigh Lynch, MSc, and Thomas Parker, PhD]]>
What APA Is Doing for You: Update on Clozapine REMS
In November 2021, the Food and Drug Administration (FDA) instituted a new Clozapine Risk Evaluation and Mitigation Strategy (REMS) to…
Read More
